tbuckley/cabot-search huggingface dataset:
EFFECTS OF TETRACYCLINE AND DEGRADATION PRODUCTS
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Renal Transplantation in Polycystic Renal Disease
Authors: Donald C. Martin
Journal: JAMA (1967)

A 37-year-old man with apparent familial polycystic renal disease reached a terminal phase of uremia in 1964. Renal transplantation was carried out from the patient's mother in July of the same year. The recipient enjoys good renal function more than three years following transplantation. This patient's polycystic kidneys were left in at the time of transplantation and have since been observed to be shrinking in size. The patient also has an erythremia (polycythemia vera) following transplantation, which persists more than three years postoperatively.
BIO-CHEMISTRY AS A RECOGNIZED MEDICAL SPECIALTY.
Journal: JAMA (1897)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
European Perspectives
Journal: Circulation (2010)

began research on arrhythmias in the early 1980s, it was an unusual topic because percutaneous transluminal coronary angioplasty had just come on the scene, and many people were interested in interventional cardiology.He says, "In many institutions, the existence of arrhythmias was more or less denied.I hoped to get involved, and I wanted to advance our knowledge in this field."Professor Hohnloser studied medicine at the University of Freiburg, Freiburg, Germany, where his father, also a cardiologist, studied medicine and his daughter has just been accepted as a medical student.It was the early 1980s, and invasive electrophysiology was in its infancy; a few years earlier, the first invasive electrophysiology study had been performed in a human. "This Paper Was Published in Circulation, So It Wasn't a Bad Manuscript"After finishing medical school, Professor Hohnloser spent 2 years as a research assistant in the Department of Physiology at Freiburg, and then he joined the cardiology group for 2 years doing clinical trials, with the aim of following it with a fellowship in the United States.As a result, Professor Hohnloser spent almost 2 years in Boston, Mass,
Survival outcomes of breast cancer in pregnancy
Authors: V. Maheshwari, J. Falk, D. Landsittel, T. Seenivasan, R. Johnson, H. Edington, E. Avissar, V. Vogel
Journal: Journal of Clinical Oncology (2004)

854 Background: Pregnancy-associated breast carcinoma is defined as breast cancer diagnosed either during pregnancy or one year post partum. Pregnancy may delay diagnosis and/or therapy and potentially worsen outcomes. Methods: We evaluated the presentation and survival outcomes of 47 consecutive patients presenting with breast cancer during or <1 year after pregnancy at our institution between 1990 and 2001 and compared them to age- and stage-matched women drawn from a national data base. One woman with cystocsarcoma phylloides and another with a desmoid tumor are not included in this analysis. Data were collected for TNM staging, ER/PR status, type of treatments, and survival. Results: Forty-six women were white, and 24 (51%) were diagnosed while pregnant; 23 (49%) were diagnosed within 1 year of parturition. Their mean age was 33.2 years (median=33). At presentation, 80% (n=36) had clinical/pathological stage 0-II tumors; 3 presented with metastatic disease. Axillary lymph nodes were negative in 19 (42%) and positive in 58%. Family history of breast cancer was positive in 29 (67.4%). ER was positive in 10 women (25.6%), and PR was positive in 17 (43.6%). Primary therapy included breast conservation and radiation (n=26, 56.5%), modified radical mastectomy (n=18, 39.1%), or none (n=2, 4.3%). Adjuvant chemotherapy was given to 38 (84.4%); 7 of these (15.2%) had preoperative chemotherapy. With a median follow-up of 39 months, 30 patients are alive (63.8%), and 17 have died (36.2%); 26 women (55.3%) are alive with no evidence of disease and 4 are alive with disease. Using the proportional hazards model, age was not significantly associated with survival (p=0.92). Five-year survival was also compared to the NCI SEER data controlling for age and stage. Although the number of subjects in our series is small, 5-year survival proportions among women in the SEER database were not significantly different for women with pregnancy-associated breast cancer (p=0.39). Conclusion: After controlling for age and stage, pregnancy does not appear to adversely affect the outcome of treatment for breast cancer. No significant financial relationships to disclose.
Laws ban minors' tobacco purchases, but enforcement is another matter
Authors: T. F. Kirn
Journal: JAMA (1987)

GREGORY CONNOLLY, DMD, says that recently, on his way to give a speech about tobacco and minors, he stopped into a local convenience store in Massachusetts to buy a soft drink. A 15-year-old boy in front of him in the checkout line was buying a pack of Marlboros. Connolly says he decided to speak up, though he claims he is usually not the type to be so bold. The clerk, he says, "laughed." Connolly repeated himself. There is a law against the sale of tobacco to minors in Massachusetts, he said. Again, the clerk laughed, and told him that there was no such law. So, Connolly pulled out his badge as director of the Office for Nonsmoking and Health of the Massachusetts Department of Public Health. He threatened to call the police. At this point, Connolly says, "It turned into something like out of a Woody Allen movie. It was
Issues of Drugs and Sports Gain Attention as Olympic Games Open in South Korea
Authors: Virginia S. Cowart
Journal: JAMA (1988)

THE OLYMPIC GAMES open in Seoul, South Korea, tomorrow. With this and other recent events, the subjects of drug use by athletes and drug testing come to public attention again. Recent developments make it likely that international agreement on drug testing and sanctions can be achieved, although the effect on athlete drug use may not be seen for some time. Meanwhile, the National Collegiate Athletic Association (NCAA) says drug testing will continue despite a California court ruling that exempts Stanford University athletes from participating. On another front, the experience of a group of Oregon medical students in trying to educate high school students about the dangers of anabolic steroids suggests that any educational effort needs to be carefully examined for its impact. With a new study showing that about 7% of male high school seniors have used anabolic steroids, it is obvious that chemical performance enhancement remains a serious subject
SWOG S1505: A randomized phase II study of perioperative mFOLFIRINOX vs. gemcitabine/nab-paclitaxel as therapy for resectable pancreatic adenocarcinoma.
Authors: Davendra Sohal, Shannon L McDonough, Syed A. Ahmad, Namita Gandhi, Muhammad Shaalan Beg, Andrea Wang-Gillam, Katherine A Guthrie, Andrew M. Lowy, Philip Agop Philip, Howard S. Hochster
Journal: Journal of Clinical Oncology (2016)

TPS4151 Background: Clinical outcomes after curative therapy for resectable pancreatic ductal adenocarcinoma (PDA) remain suboptimal. Series show that 70-85% of patients die of systemic recurrence. Improved overall survival (OS) in the metastatic setting with the use of multi-agent chemotherapy regimens (FOLFIRINOX, gemcitabine/nab-paclitaxel) holds the promise of progress in the curative setting as well. However, aggressive systemic therapy is usually not feasible after major pancreatic surgery. Therefore, early control of systemic disease by increased preoperative chemotherapy delivery may improve outcomes. Furthermore, the perioperative platform facilitates early identification of patients with chemotherapy-resistant tumors and allows prospective biomarker studies, which can be used to test targeted therapies in the future. Methods: This is a randomized phase II study intended to choose the most promising perioperative regimen to test in a larger trial. Eligibility requirements include adult patients with an ECOG PS of 0 or 1, a confirmed histopathologic diagnosis of PDA, and resectable disease as confirmed by central radiology review: no involvement of the celiac, common hepatic, or superior mesenteric arteries (and, if present, variants); no involvement, or < 180° interface between tumor and vessel wall, of the portal or superior mesenteric veins; patent portal vein/splenic vein confluence; no metastases. Treatment includes 12 weeks [either 6 doses of mFOLFIRINOX (5-fluorouracil, irinotecan, oxaliplatin – without bolus 5-FU and leucovorin), or 9 doses of gemcitabine/nab-paclitaxel, on standard schedules] of preoperative chemotherapy, followed by surgical resection and 12 weeks of identical postoperative chemotherapy. Primary outcome is 2-year OS, using a “pick the winner” design with minimum two-year OS of 40% assuming a 58% alternative hypothesis, 88% power, and a 1-sided α of 0.05, providing 90% probability of selecting the better regimen with a total sample size of 112 patients. Correlative studies are planned. The study opened through the National Clinical Trials Network (ClinicalTrials.gov Registry Number: NCT02562716). Clinical trial information: NCT02562716.
c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis
Authors: Zuoning Han, David L. Boyle, Lufen Chang, Brydon Bennett, Michael Karin, Li Yang, Anthony M. Manning, Gary S. Firestein
Journal: Journal of Clinical Investigation (2001)

Mitogen-activated protein kinase (MAPK) cascades are involved in inflammation and tissue destruction in rheumatoid arthritis (RA). In particular, c-Jun N-terminal kinase (JNK) is highly activated in RA fibroblast-like synoviocytes and synovium. However, defining the precise function of this kinase has been difficult because a selective JNK inhibitor has not been available. We now report the use of a novel selective JNK inhibitor and JNK knockout mice to determine the function of JNK in synoviocyte biology and inflammatory arthritis. The novel JNK inhibitor SP600125 (anthra[1,9-cd]pyrazol-6(2H)-one) completely blocked IL-1–induced accumulation of phospho-Jun and induction of c-Jun transcription in synoviocytes. Furthermore, AP-1 binding and collagenase mRNA accumulation were completely suppressed by SP600125. In contrast, complete inhibition of p38 had no effect, and ERK inhibition had only a modest effect. The essential role of JNK was confirmed in cultured synoviocytes from JNK1 knockout mice and JNK2 knockout mice, each of which had a partial defect in IL-1–induced AP-1 activation and collagenase-3 expression. Administration of SP600125 modestly decreased the rat paw swelling in rat adjuvant-induced arthritis. More striking was the near-complete inhibition of radiographic damage that was associated with decreased AP-1 activity and collagenase-3 gene expression. Therefore, JNK is a critical MAPK pathway for IL-1–induced collagenase gene expression in synoviocytes and in joint arthritis, indicating that JNK is an important therapeutic target for RA.
EDMOND HALLEY (1656-1742)— ASTRONOMER AND VITAL STATISTICIAN
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Reply
Authors: P. Collin, T. Reunala, A. Pasternack
Journal: Gut (1995)

EDITOR,-Eighteen coeliac patients and nine control patients in our study suffered from autoimmune thyroid diseases.We included all patients who had a past history of autoimmune thyroid disease.It is possible that the increased frequency among coeliac patients is real, even though the difference was not statistically significant.The findings of Counsell et al suggest that the association between these diseases is more than coincidental.Supporting this, in another study that we conducted, four (4/8%) of 83 patients with autoimmune thyroid disease had silent coeliac disease, when they were screened by the IgA reticulin and gliadin antibody tests.1It is correct that we did not search for autoimmune thyroid diseases vigorously among either coeliac patients or control patients.Some cases may have remained undiagnosed in both groups.We consider that prospective controlled studies would be essential to confirm the association between these diseases.We agree with Counsell et al that thyroid function should be examined in all coeliac patients.Nowadays we also screen all patients with autoimmune thyroid diseases by retic- ulin and gliadin antibody tests.
Noncardiovascular Disease Outcomes During 6.8 Years of Hormone Therapy
Authors: Stephen Hulley, Curt Furberg, Elizabeth Barrett-Connor, Jane Cauley, Deborah Grady, William Haskell, Robert Knopp, Maureen Lowery, Suzanne Satterfield, Helmut Schrott, Eric Vittinghoff, Donald Hunninghake
Journal: JAMA (2002)

ContextThe Heart and Estrogen/progestin Replacement Study (HERS) was a randomized trial of estrogen plus progestin therapy after menopause.ObjectiveTo examine the effect of long-term postmenopausal hormone therapy on common noncardiovascular disease outcomes.Design and SettingRandomized, blinded, placebo-controlled trial of 4.1 years' duration (HERS) and subsequent open-label observational follow-up for 2.7 years (HERS II), carried out between 1993 and 2000 in outpatient and community settings at 20 US clinical centers.ParticipantsA total of 2763 postmenopausal women with coronary disease and average age of 67 years at enrollment in HERS; 2321 women (93% of those surviving) consented to follow-up in HERS II.InterventionParticipants were randomly assigned to receive 0.625 mg/d of conjugated estrogens plus 2.5 mg of medroxyprogesterone acetate (n = 1380) or placebo (n = 1383) during HERS; open-label hormone therapy was prescribed at personal physicians' discretion during HERS II. The proportions with at least 80% adherence to hormones declined from 81% (year 1) to 45% (year 6) in the hormone group and increased from 0% (year 1) to 8% (year 6) in the placebo group.Main Outcome MeasuresThromboembolic events, biliary tract surgery, cancer, fracture, and total mortality.ResultsComparing women assigned to hormone therapy with those assigned to placebo, the unadjusted intention-to-treat relative hazard (RH) for venous thromboembolism declined from 2.66 (95% confidence interval [CI], 1.41-5.04) during HERS to 1.40 (95% CI, 0.64-3.05) during HERS II (P for time trend = .08); it was 2.08 overall for the 6.8 years (95% CI, 1.28-3.40), and 3 of the 73 women with thromboembolism died within 30 days due to pulmonary embolism. The overall RH for biliary tract surgery was 1.48 (95% CI, 1.12-1.95); for any cancer, 1.19 (95% CI, 0.95-1.50); and for any fracture, 1.04 (95% CI, 0.87-1.25). There were 261 deaths among those assigned to hormone therapy and 239 among those assigned to placebo (RH, 1.10; 95% CI, 0.92-1.31). Adjusted and as-treated analyses did not alter our conclusions.ConclusionsTreatment for 6.8 years with estrogen plus progestin in older women with coronary disease increased the rates of venous thromboembolism and biliary tract surgery. Trends in other disease outcomes were not favorable and should be assessed in larger trials and in broader populations.
Hands-on
Authors: Richard J. Rosenthal
Journal: JAMA (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Laboratory diagnosis of hemoglobinopathies
Authors: R. M. Schmidt
Journal: JAMA (1973)

A successful voluntary hemoglobinopathy screening program should have as its goals effective, accurate counseling, preventive medicine, and education. Techniques that detect only the presence of hemoglobin S would not allow these goals to be fulfilled. The Center for Disease Control is currently offering training courses in laboratory methods of hemoglobinopathy detection for anyone involved in hemoglobinopathy screening. These courses, which are free, stress cellulose acetate electrophoresis as the initial screening test. Besides being inexpensive, the test is easy to perform, allows differentiation of sickle cell disease (eg, SS, SC) from the relatively benign carrier state, and detects other common hemoglobin abnormalities so that effective counseling is possible. The solubility (dithionite) test is used to confirm the presence of a sickling hemoglobin.
Friedrich von Recklinghausen (1833-1910). German pathologist
Journal: JAMA (1968)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Paecilomyces marquandii cellulitis in a kidney transplant patient
Authors: L. Naldi, S. Lovati, C. Farina, E. Gotti, T. Cainelli
Journal: British Journal of Dermatology (2000)

SIR, Paecilomyces species are ubiquitous saprophytic fungi that rarely cause human infection. There have been several reports of cutaneous infection from Paecilomyces spp., particularly P. lilacinus. We report a renal transplant patient with P. marquandii cellulitis. A 50‐year‐old white man, who had undergone renal transplantation 15 years previously due to chronic glomerulonephritis, was seen 20 days after the appearance of a slowly spreading erythematous area on the anterior aspect of his left leg. There was no history of apparent trauma, but he occasionally worked outdoors in his garden. He had been treated for venous thrombosis of the right leg several years previously. Since undergoing renal transplantation, he had been taking azathioprine and prednisone. There was no history of treatment with steroid infusions or OKT3 following transplantation. Examination revealed a 5 × 3 cm erythematous indurated plaque, rich red in colour, surmounted by a few haemorrhagic blisters (Fig. 1). No inguinal lymph nodes were palpable. The patient was afebrile but complained of moderate leg pain. The results of laboratory analyses including haematocrit, white cell count, erythrocyte sedimentation rate, C‐reactive protein, liver and renal function were normal.
Editorial Board
Authors: Zuhair Ballas, Iowa City, Iowa Deputy, David Huston, Rachel Miller, New York, N Associate, Andrea Apter, Leonard Philadelphia, St Bacharier, Claus Louis, Joshua Bachert, Boston Boyce, Javier Chinen, Raif Geha, Corinne Keet, Carole Ober, David Peden, Harald Renz, Marburg Germany, Marc Rothenberg, Cincinnati Ohio, Hirohisa Saito
Journal: Journal of Allergy and Clinical Immunology (2020)